WuXi PharmaTech Shanghai Rodent Facility Awarded AAALAC Accreditation
Dec 18, 2008
December 18, 2008 – Shanghai, China – WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its rodent facility in Shanghai has received accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's rodent facility is committed to the highest level of animal care and research practices.
AAALAC noted the following in its official approval letter: "The WuXi PharmaTech China management and staff are commended for providing good facilities and programs for the care and use of laboratory animals. Especially noteworthy were the strong institutional commitment to the animal care and use program; the conscientious and capable Institutional Animal Care and Use Committee (IACUC); the knowledgeable and experienced animal care and use staff; excellent documentation (Standard Operating Procedures and guidelines) and records; and a well maintained, state-of-the-art facility. The attention to detail and completeness was exceptional."
"The AAALAC accreditation comes as a result of our efforts in expanding service capabilities from chemistry to preclinical drug development including drug metabolism (DMPK) and toxicology," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We are pleased to receive such high praise from the leading independent world body on the care and use of laboratory animals and we could not be more proud of the report issued by AAALAC. We are confident of being at the top of our industry with the endorsement of AAALAC."
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.